The White House recently unveiled a strategy to combat the escalating threat of xylazine, often called "tranq," a potent animal tranquilizer increasingly mixed with fentanyl. While stopping short of officially classifying xylazine under stricter regulations, the plan emphasizes research and testing to gauge the drug's prevalence. Federal agencies will also explore supply chain disruptions and potential regulatory actions.

Image: A xylazine-induced wound. (Courtesy Frank Rodriguez)

Xylazine, primarily used for animal sedation and anesthesia, is not approved for human consumption and lacks a known antidote. Its unregulated status poses a significant challenge, though some states have moved to classify it as a Schedule III drug. Rahul Gupta, director of the White House National Drug Control Policy, highlighted the administration's focus on addressing xylazine's growing presence and the need for evidence-based solutions.

The Drug Enforcement Agency (DEA) reported finding "tranq" in 48 states as of March, suggesting cost-cutting measures by suppliers. The drug's veterinary prescription status raises questions about how it's obtained for illicit purposes. The CDC reports a significant increase in xylazine-related fentanyl deaths between 2019 and 2022, a trend potentially worsening given recent reports and viral videos showcasing the drug's devastating effects, including severe tissue damage.

Image: Another example of a xylazine-related wound. (Courtesy Frank Rodriguez)

The White House strategy calls for research into harm reduction strategies and disrupting the illegal supply chain. Several states have already taken steps to schedule xylazine, enabling greater regulatory control. In April, the White House officially designated xylazine as an "emerging threat," leading to various warnings from federal agencies. Bipartisan legislation has also been introduced in Congress to classify xylazine as a Schedule III drug, aiming to provide law enforcement with more tools to combat its spread.

Image: A xylazine wound on a hand. (Courtesy Fran Rodriguez)